Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses (Details 1)

v2.4.0.8
Acquisitions, Investments, and Licenses (Details 1) (Cytochroma acquisition [Member], USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Cytochroma acquisition [Member]
       
Pro Forma Result of Combined Companies        
Revenues $ 23,821 $ 12,393 $ 55,197 $ 23,351
Net loss (4,353) (10,840) (42,583) (20,050)
Net loss attributable to common shareholders $ (3,394) $ (11,398) $ (41,496) $ (21,164)
Basic and diluted loss per share (in dollars per share) $ (0.01) $ (0.04) $ (0.13) $ (0.07)